Neurocrine Biosciences, Inc.
NBIX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $2 | $2 | $1 | $1 |
| % Growth | 24.8% | 26.8% | 31.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $2 | $2 | $1 | $1 |
| % Margin | 98.6% | 97.9% | 98.4% | 98.7% |
| R&D Expenses | $1 | $1 | $0 | $0 |
| G&A Expenses | $1 | $0 | $0 | $0 |
| SG&A Expenses | $1 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $2 | $1 | $1 |
| Operating Income | $1 | $0 | $0 | $0 |
| % Margin | 24.2% | 13.3% | 16.7% | 9% |
| Other Income/Exp. Net | -$0 | $0 | -$0 | -$0 |
| Pre-Tax Income | $0 | $0 | $0 | $0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 14.5% | 13.2% | 10.4% | 7.9% |
| EPS | 3.4 | 2.56 | 1.61 | 0.95 |
| % Growth | 32.8% | 59% | 69.5% | – |
| EPS Diluted | 3.29 | 2.47 | 1.56 | 0.92 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $1 | $0 | $0 | $0 |
| % Margin | 27.2% | 22% | 17.8% | 12.2% |